[1] Lee AW,Ng WT,Hung WM,et al. Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient-and treatment-related risk factors. Int J Radiat Oncol Biol Phys,2009,73:1121-1128.
[2] Soussain C,Ricard D,Fike JR,et al. CNS complications of radiotherapy and chemotherapy. Lancet,2009,374:1639-1651.
[3] Kim JH,Brown SL,Jenrow KA,et al. Mechanisms of radiation-induced brain toxicity and implications for future clinical trials. J Neurooncol,2008,87:279-286.
[4] Gallet P,Phulpin B,Merlin JL,et al. Long-term alterations of cytokines and growth factors expression in irradiated tissues and relation with histological severity scoring. PLoS One,2011,6:e29399.
[5] Coderre JA,Morris GM,Micca PL,et al. Late effects of radiation on the central nervous system: role of vascular endothelial damage and glial stem cell survival. Radiat Res,2006,166:495-503.
[6] Chen J,Dassarath M,Yin Z,et al. Radiation induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: a review of new avenues in its management. Radiat Oncol,2011,6:128.
[7] Sobrero A,Ackland S,Clarke S,et al. Phase Ⅳ study of Bevacizumab in combination with infusional fluorouracil,leucovorin and irinotecan(FOLFIRI) in first-line metastatic colorectal cancer. Oncology,2009,77:113-119.
[8] Reck M,von PJ,Zatloukal P,et al. Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or Bevacizumab as first-linetherapy for nonsquamous non-small-cell lung cancer: AVAil. J
Clin Oncol,2009,27:1227-1234.
[9] Escudier B,Pluzanska A,Koralewski P,et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised,double-blind phase Ⅲ trial. Lancet,2007,370:2103-2111.
[10] Van Meter ME,Kim ES. Bevacizumab: current updates in treatment. Curr Opin Oncol,2010,22:586-591.
[11] Willett CG,Boucher Y,di Tomaso E,et al. Direct evidence that the VEGF-specific antibody Bevacizumab has antivascular effects in human rectal cancer. Nat Med,2004,10:145-147.
[12] Li X,Hu Y,Sun X,et al. Bevacizumab for Neovascular Age-Related Macular Degeneration in China. Ophthalmology,2012,In press.
[13] Nonoguchi N,Miyatake S,Fukumoto M,et al. The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles. J Neurooncol,2011,105:423-431.
[14] Williams KJ,Telfer BA,Shannon AM,et al. Inhibition of vascular endothelial growth factor signalling using cediranib(RECENTINTM;AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts. Br J Radiol,2008,81:21-27.
[15] Gonzalez J,Kumar AJ,Conrad CA,et al. Effect of Bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys,2007,67:323-326.
[16] Wong ET,Huberman M,Lu XQ,et al. Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol,2008,26:5649-5650.
[17] Torcuator R,Zuniga R,Mohan YS,et al. Initial experience with Bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol,2009,94:63-68.
[18] Levin VA,Bidaut L,Hou P,et al. Randomized double-blind placebo-controlled trial of Bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys,2011,79:1487-1495.
[19] Furuse M,Kawabata S,Kuroiwa T,et al. Repeated treatments with Bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol,2011,102:471-475.
[20] Chamberlain MC,Eaton KD,Fink J. Radiation-induced myelopathy: treatment with Bevacizumab. Arch Neurol,2011,68:1608-1609.
[21] Benoit A,Ducray F,Cartalat-Carel S,et al. Favorable outcome with Bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis. J Neurol,2011,258:328-329.
[22] Jeyaretna DS,Curry WT Jr,Batchelor TT,et al. Exacerbation of cerebral radiation necrosis by Bevacizumab. J Clin Oncol,2011,29:159-162.
[23] Liu AK,Macy ME,Foreman NK. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys,2009,75:1148-1154.
[24] Matuschek C,Bolke E,Nawatny J,et al. Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlenther Onkol,2011,187:135-139.
[25] Gordon MS,Margolin K,Talpaz M,et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol,2001,19:843-850.
[26] Kelly PJ,Dinkin MJ,Drappatz J,et al. Unexpected late radiation neurotoxicity following Bevacizumab use: a case series. J Neurooncol,2011,102:485-490.
[27] Narazaki M,Tosato G. Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood,2006,107:3892-3901. |
|
|
2013, Vol. 22 
